tbuckley/cabot-search huggingface dataset:
FRI-372-Next generation sequenzing outperforms standard microbiological cultivation for detection of bacteria in the biliary tract in patients with ischemic type biliary lesions and/or anastomotic stricture
Authors: Björn Grobe, Philipp Solbach, Freya Wellhöner, Friederike Klein, Vital Marius, Michael P. Manns, Dietmar H. Pieper, Von Hahn Thomas, Torsten Voigtländer, Henrike Lenzen, Benjamin Heidrich
Journal: Journal of Hepatology (2019)
EGFR mutation pattern in African American population in a community-based academic center.
Authors: Haiying Cheng, Cengiz Inal, Yuanquan Yang, Rasim A. Gucalp, Missak Haigentz, Stuart H. Packer, Changcheng Zhu, Kevin Wilson, Roman Perez-Soler
Journal: Journal of Clinical Oncology (2015)

8069 Background: The two most common EGFR mutations, L858R in exon 21 and deletions in exon19, represent around 90% of all EGFR mutations in NSCLC and convey sensitivity to EGFR TKIs. Little is known about the patterns of EGFR mutations in different racial groups. Montefiore Medical Center (MMC), a community based academic center, treats a large minority patient population. For example, 33% (693/2104) of patients with lung cancer were identified as African American from 01/2009 to 06/2014. We initiated reflex molecular testing on all non-squamous NSCLC patients in 01/2012 at MMC. Methods: We retrospectively reviewed our cancer registry database from 01/2009 to 06/2014 and analyzed all non-squamous NSCLC patients with pathology available in our system for rates and patterns of EGFR mutations. EGFR testing was performed by Integrated Oncology (Labcorp) by PCR-based technology. Results: 1032 patients with non-squamous NSCLC had their pathological diagnosis at MMC: 386 (37.4%) were African American, 475 (46%) white, 46 (4.5%) other (Asian and others), and 125 (12.1%) race unknown, respectively. EGFR mutation analysis was performed in 446 patients and 63 were positive for EGFR mutations. The EGFR mutation rate was 14.1% (63/446) for all races, 12.4% (22/178) for African Americans and 14% (27/193) for whites. Interestingly, 25.4% (16/63) of mutations were uncommon EGFR mutations on exon 18 or exon 20, which is higher than the rates reported in the literature (~10%). In particular, 31.8% (7/22) of African Americans with EGFR mutations had uncommon mutations. The mean age at diagnosis of these 7 patients was 66 years, 5 were female, 2 never-smokers, and 5 had stage 3 or 4 disease. The types of uncommon mutations included S768I, V769L, N771_H773dupNPH, H773L, V774M mutations in Exon 20, G719A mutation in Exon 18 or combinations. Conclusions: This is the first report of a high uncommon EGFR mutation rate in African American lung cancer patients. Most uncommon EGFR mutations are less sensitive to EGFR TKIs than L858R and del 19. These results justify confirmation studies in larger cohorts of patients.
THU-468-SLU7 controls genome integrity: New role of truncated SRSF3 proteins
Authors: Maddalen Jimenez, Raquel urtasun, María Elizalde, María Azkona, Maria Arechederra, Maria U Latasa, Iker Uriarte, Marina Bárcena-Varela, Gloria Álvarez-Sola, Leticia Colyn, Eva Santamaria, Bruno Sangro, Carlos Rodriguez-Ortigosa, Maite G Fernandez-Barrena, Matías A Avila, Carmen Berasain
Journal: Journal of Hepatology (2019)
Clinical utility of genomic analysis in adults with idiopathic liver disease
Authors: Aaron Hakim, Xuchen Zhang, Angela DeLisle, Elif A. Oral, Daniel Dykas, Kaela Drzewiecki, David N. Assis, Marina Silveira, Jennifer Batisti, Dhanpat Jain, Allen Bale, Pramod K. Mistry, Silvia Vilarinho
Journal: Journal of Hepatology (2019)
On Art and Therapy
Authors: Jayati Das Munshi
Journal: BMJ (1999)

Art therapy is one of those disciplines I know little about. I am told by colleagues who have experienced it first hand on placement that I'm not missing much. Which, I suppose, is hardly surprising, given the current climate of stark disapproval against which therapies with no evidence base have to battle against in order to survive. It was with this in mind that I started to read Martina Thomson's On Art and Therapy. 

Art …
SAT-248-Patients treated for HCV and listed for LT in a French multicenter study: What happens at 3 years?
Authors: Lucy Meunier, Georges-Philippe Pageaux, Sylvie Radenne, Anais Vallet Pichard, Pauline Houssel-Debry, Christophe Duvoux, Danielle Botta Fridlund, Victor De Ledinghen, Filomena Conti, Rodolphe Anty, Vincent Di Martino, Marilyne Gratien, Vincent Leroy, Pascal Lebray, Laurent Alric, Armand Abergel, Jérôme Dumortier, Camille Besch, Montialoux Helene, Didier Samuel, Jean-Charles Duclos-Vallée, Audrey Coilly
Journal: Journal of Hepatology (2019)
The incidence of pregnancy hypertension in India, Pakistan, Mozambique, and Nigeria: A prospective population-level analysis
Authors: Laura A. Magee, Sumedha Sharma, Hannah L. Nathan, Olalekan O. Adetoro, Mrutynjaya B. Bellad, Shivaprasad Goudar, Salécio E. Macuacua, Ashalata Mallapur, Rahat Qureshi, Esperança Sevene, John Sotunsa, Anifa Valá, Tang Lee, Beth A. Payne, Marianne Vidler, Andrew H. Shennan, Zulfiqar A. Bhutta, Peter von Dadelszen
Journal: PLoS Medicine (2019)

Most pregnancy hypertension estimates in less-developed countries are from cross-sectional hospital surveys and are considered overestimates. We estimated population-based rates by standardised methods in 27 intervention clusters of the Community-Level Interventions for Pre-eclampsia (CLIP) cluster randomised trials.CLIP-eligible pregnant women identified in their homes or local primary health centres (2013-2017). Included here are women who had delivered by trial end and received a visit from a community health worker trained to provide supplementary hypertension-oriented care, including standardised blood pressure (BP) measurement. Hypertension (BP ≥ 140/90 mm Hg) was defined as chronic (first detected at <20 weeks gestation) or gestational (≥20 weeks); pre-eclampsia was gestational hypertension plus proteinuria or a pre-eclampsia-defining complication. A multi-level regression model compared hypertension rates and types between countries (p < 0.05 considered significant). In 28,420 pregnancies studied, women were usually young (median age 23-28 years), parous (53.7%-77.3%), with singletons (≥97.5%), and enrolled at a median gestational age of 10.4 (India) to 25.9 weeks (Mozambique). Basic education varied (22.8% in Pakistan to 57.9% in India). Pregnancy hypertension incidence was lower in Pakistan (9.3%) than India (10.3%), Mozambique (10.9%), or Nigeria (10.2%) (p = 0.001). Most hypertension was diastolic only (46.4% in India, 72.7% in Pakistan, 61.3% in Mozambique, and 63.3% in Nigeria). At first presentation with elevated BP, gestational hypertension was most common diagnosis (particularly in Mozambique [8.4%] versus India [6.9%], Pakistan [6.5%], and Nigeria [7.1%]; p < 0.001), followed by pre-eclampsia (India [3.8%], Nigeria [3.0%], Pakistan [2.4%], and Mozambique [2.3%]; p < 0.001) and chronic hypertension (especially in Mozambique [2.5%] and Nigeria [2.8%], compared with India [1.2%] and Pakistan [1.5%]; p < 0.001). Inclusion of additional diagnoses of hypertension and related complications, from household surveys or facility record review (unavailable in Nigeria), revealed higher hypertension incidence: 14.0% in India, 11.6% in Pakistan, and 16.8% in Mozambique; eclampsia was rare (<0.5%).Pregnancy hypertension is common in less-developed settings. Most women in this study presented with gestational hypertension amenable to surveillance and timed delivery to improve outcomes.This study is a secondary analysis of a clinical trial - ClinicalTrials.gov registration number NCT01911494.
THU-119-Direct-acting antiviral regimens without protease inhibitors may help maintain a healthy lipid profile after hepatitis C eradication
Authors: Vanesa Bernal Monterde, Diego Casas-Deza, Eva Fernandez Bonilla, Silvia Espina, Marta Fernández Esgueva, Ana Martinez-Sapiña, Javier Fuentes, Jose M Arbones Mainar
Journal: Journal of Hepatology (2019)
SAT-285-Fibroscan-based score for detection of active nash and significant fibrosis is better than fib-4 in 361 chronic hepatitis B patients with non-alcoholic fatty liver disease
Authors: Xiaoling Chi, Meijie Shi, Huanming Xiao, Pengtao Zhao, Yubao Xie, Junmin Jiang, Gaoshu Cai, Minling Cao, Hongcai Liang, Yingxian Li, Huijun Chen, chaozhen zhang, sheng li, shuduo wu
Journal: Journal of Hepatology (2019)
High-Throughput Contractility Assay for Human Stem Cell-Derived Cardiomyocytes
Authors: Jason W. Miklas, Max R. Salick, Deok-Ho Kim
Journal: Circulation Research (2019)

W ith the high rate of cardiovascular disease and cardi- ovascular comorbidities, the burden on the healthcare system in the United States has reached $329.7 billion dollars per year. 1 As developing countries become more industrialized, they also become susceptible to entering a phase, in which cardiovascular disease (a noncommunicable disease) begins to outrank communicable diseases such as malaria, tuberculosis, and HIV/AIDS.However, the rate of novel drug discovery dropped 33% between the years 2000 and 2009 as compared to the prior decade, whereas the price of bringing a new drug to market cost over $50 billion in the United States in 2008. 2 Consequently, great effort has been made to identify new therapeutics, yet few therapeutics have been found because of the limitations of current techniques. Article, see p 1172Fortunately, cardiomyocytes are one of the most readily produced and distinguishable cell types that can be differentiated from pluripotent stem cells (PSC). 3Human PSCderived cardiomyocytes (hPSC-CMs), while immature, have the machinery at hand to express all the electrophysiological ion channels found in an adult human cardiomyocyte, along with their critical sarcomere structures.These repeating sarcomeres, along with the sarcolemma-binding costamere structures, provide cardiomyocytes with their mechanotransductive properties.Because of the indispensable nature of these protein complexes, mutations affecting sarcomere and costamere protein-coding genes lead to severe and often lethal diseases.Additionally, gene editing technologies, such as CRISPR/ Cas9, have progressed alongside improved hPSC culture and patient-derived somatic cell reprogramming methods to enable controlled in vitro studies of these diseases.With these combined tools, researchers can now identify specific drugs that may aid these patients in a precision medicine approach.
An Unusual False-Positive Uptake of Radioiodine Caused by Metallic Implants
Authors: Lina Liu, Yu Chen, Tian Tian, Rui Huang, Bin Liu
Journal: Clinical Nuclear Medicine (2019)

Abstract A 36-year-old woman with a history of papillary thyroid cancer underwent radioiodine remnant ablation using 131 I. Postablation whole body 131 I scintigraphy revealed increased activity not only in the thyroid bed but also in the right upper thigh. SPECT/CT images localized the activity to the metallic implants of the right femur, implanted 3 years earlier after the right femoral cyst resection.
Dynamic Stress Computed Tomography Perfusion With a Whole-Heart Coverage Scanner in Addition to Coronary Computed Tomography Angiography and Fractional Flow Reserve Computed Tomography Derived
Authors: Gianluca Pontone, Andrea Baggiano, Daniele Andreini, Andrea I. Guaricci, Marco Guglielmo, Giuseppe Muscogiuri, Laura Fusini, Margherita Soldi, Alberico Del Torto, Saima Mushtaq, Edoardo Conte, Giuseppe Calligaris, Stefano De Martini, Cristina Ferrari, Stefano Galli, Luca Grancini, Paolo Olivares, Paolo Ravagnani, Giovanni Teruzzi, Daniela Trabattoni, Franco Fabbiocchi, Piero Montorsi, Mark G. Rabbat, Antonio L. Bartorelli, Mauro Pepi
Journal: JACC. Cardiovascular imaging (2019)
FRI-098-Targeting cholesterol with atorvastatin protects against valproic acid-induced sensitization to acetaminophen hepatotoxicity
Authors: Sandra Torres, Susana Núñez, Naroa Insausti-Urkia, Estel Solsona-Vilarrasa, Vicent Ribas, Carmen García-Ruiz, José Fernandez-Checa
Journal: Journal of Hepatology (2019)
SAT-350-YH25724, a novel long-acting GLP-1/FGF21 dual agonist, exhibits marked anti-fibrotic effects in different experimental models of liver fibrosis
Authors: Dohoon Kim, Junhwan Kim, Tae Wang Kim, Han Hong, Hyun Choi, Ji-Eun Yang, Da-Na Jeong, Mi Kyeong Ju, Minji Seo, Su Kyung Kim, Ju-Young Park, Byung Hyun Choi, Han-Joo Kim, Kyoung Kyu Ahn, Jong-Gyun Kim, Pierre Bedossa, Vlad Ratziu, Se-Woong Oh, Soongyu Choi
Journal: Journal of Hepatology (2019)
THU-182-The PRIORITIZE study: A pragmatic, randomized study of oral regimens for hepatitis C-transforming decision-making for patients, providers, and stakeholders
Authors: Mark Sulkowski, Juhi Moon, Kenneth E. Sherman, Jama Darling, Andrew Muir, Mandana Khalili, Dawn Fishbein, Federico Hinestrosa, Mitchell Shiffman, Adrian Di Bisceglie, Rajender Reddy, Brian Pearlman, Anna Lok, Michael W. Fried, Paul Stewart, Joy Peter, Summer Wadsworth, Monika Vainorius, Larry Michael, Donna Evon, Jodi Segal, David R. Nelson
Journal: Journal of Hepatology (2019)
GS-07-Real-world safety, effectiveness, and patient-reported outcomes in patients with chronic hepatitis C virus infection treated with glecaprevir/pibrentasvir: Data from the German Hepatitis C-Registry
Authors: Markus Cornberg, Albrecht Stoehr, Naumann Uwe, Hartwig Klinker, Lutz Thomas, Willibold Schiffelholz, Nazifa Qurishi, Andreas Pangerl, Kristina Lohmann, Bettina König, Karl-Georg Simon
Journal: Journal of Hepatology (2019)
Biomechanical Stress Profiling of Coronary Atherosclerosis
Authors: Pallavi Doradla, Kenichiro Otsuka, Abhijay Nadkarni, Martin Villiger, Antonios Karanasos, Laurens J.C. van Zandvoort, Jouke Dijkstra, Felix Zijlstra, Gijs van Soest, Joost Daemen, Evelyn Regar, Brett E. Bouma, Seemantini K. Nadkarni
Journal: JACC. Cardiovascular imaging (2019)
Asymptomatic Prostate Cancer Brain Metastases on 68Ga-PSMA PET/CT
Authors: Charlotte Yin, Bao Ho, Lyn Chan, Louise Emmett
Journal: Clinical Nuclear Medicine (2019)

Brain metastases from prostate cancer are rare and occur at a late stage in the natural history of the disease. Men usually present with neurological manifestations. We present a 66-year-old asymptomatic man who had incidental brain metastases detected on Ga-PSMA PET/CT, which was later confirmed on biopsy to be prostate adenocarcinoma. With newer androgen deprivation agents and improved imaging capabilities increasing the mean survival and thus the incidence of brain metastases from prostate cancer, it is important to consider this important differential not only in men who display neurological symptoms but also in men who are asymptomatic.
Guide to Medical Etiquette: the three letter abbreviation
Authors: David McAllister
Journal: BMJ (1999)

In the bad old days, doctors used obscure medical ter-minology from Latin and Greek to patronise patients and confuse the public. Thankfully, such condescension is a thing of the past. Instead, the modern doctor asserts his supremacy using the TLA (three letter abbreviation).

As a form, the TLA has much to offer the medical student. Use it correctly and you will appear to be intelligent, efficient, and dynamic--the kind of student who has not the time …
Phase III METIS study: Tumor treating fields (150 kHz) and radiosurgery for supra- and/or infratentorial brain metastases (1-10) from non-small cell lung cancer (NSCLC)
Authors: M. Mehta, V. Gondi, M. Ahluwalia, P. Brown
Journal: Annals of Oncology (2019)

Background: Tumor Treating Fields (TTFields) are non-invasive, loco-regional, anti-mitotic treatment modality comprising low intensity alternating electric fields. TTFields has demonstrated efficacy in non-small cell lung cancer (NSCLC) in in vitro and in vivo models, and in a phase I/II clinical study. TTFields treatment to the brain was safe and extended overall survival in newly-diagnosed glioblastoma. This prospective, multicenter study [NCT02831959] investigated the efficacy, safety and neurocognitive outcomes of TTFields in NSCLC patients with brain metastases. Trial design: NSCLC patients (n = 270) with 1-10 brain metastases are randomized 1:1 to stereotactic radio surgery (SRS) followed by continuous TTFields ((150 kHz, > 18 hours/day) within 7 days of SRS or supportive care. The TTFields portable device delivers TTFields to the brain using 4 transducer arrays and allows normal daily activities. Patients receive the best standard-of-care for their systemic disease. Patients are followed every two months until second intracranial progression. Patients in the control arm are allowed to cross over to TTFields arm at the time of second intracranial progression. Key inclusion criteria: KPS ≥70, new diagnosis of 1 inoperable or 2–10 supra- and/or infratentorial brain metastases from NSCLC amenable to SRS; KPS ≥70; and optimal therapy for extracranial disease. Prior WBRT or surgical resection of metastases, a single resectable lesion or recurrent brain metastases were exclusionary. Primary endpoint was time to 1st intracranial progression. Secondary endpoints included time to neurocognitive failure (HVLT, COWAT and TMT), overall survival, radiological response rate (RANO-BM and RECIST V1.1); quality-of-life; adverse events; time to first/second intracranial progression for patients with 1–4 and 5–10 brain metastases; bi-monthly intracranial progression rate from 2–12 months; and time to second intracranial and distant progression. The sample size (n = 270) was calculated using a log-rank test (Lakatos 1988 and 2002) with 80% power at a two sided alpha of 0.05 to detect a hazard ratio of 0.57. Clinical trial identification: NCT02831959. Legal entity responsible for the study: Novocure. Funding: Novocure. Disclosure: M. Mehta: Advisor/board member: Pharmacyclics; Consultant: Cavion, Novocure, Varian, Agenus, Insys, Remedy, IBA; Stock shareholder: Pharmacyclics; DSMB for Monteris. P. Brown: Personal fees (consultant): UpToDate. All other authors have declared no conflicts of interest.
Antimicrobial Treatment of the Umbilical Cord
Authors: G D Robinson
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 12161: Mortality and Clinical Endpoints After 3-6 Months, 12 Months, and 18-48 Months of Dual Antiplatelet Therapy: A Bayesian Network Meta-Analysis of Drug-Eluting Stents
Authors: John A Bittl, Yulei He
Journal: Circulation (2017)

Introduction: Meta-analyses of randomized controlled trials (RCTs) of dual antiplatelet therapy (DAPT) have produced varying conclusions about the relation between outcomes and prolonged DAPT after drug-eluting stent (DES) implantation, but reasons for disagreement are uncertain. Hypothesis: Traditional meta-analyses define DAPT duration as either “short” or “long,” which unintentionally compares outcomes at 12 months with outcomes at 12 months, because this duration has been defined as “short” DAPT in 4 RCTs and as “long” DAPT in 7 RCTs. Methods: We created a Bayesian network meta-analysis to compare outcomes after 3-6 months with the common comparator of 12 months and with 18-48 months of DAPT in 14 RCTs of DAPT duration after DES implantation. Results and Conclusions: As shown in the Figure, mortality was not increased when DAPT was increased from 3-6 to 12 months (posterior odds ratio [OR], 0.97; 95% Bayesian credible interval [BCI], 0.66–1.30), from 12 to 18-48 months (OR, 1.07; 95% BCI, 0.76–1.48), ...
Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor–engineered T Cells
Authors: Esther Drent, Renée Poels, Ruud Ruiter, Niels W.C.J. van de Donk, Sonja Zweegman, Huipin Yuan, Joost de Bruijn, Michel Sadelain, Henk M. Lokhorst, Richard W.J. Groen, Tuna Mutis, Maria Themeli
Journal: Clinical Cancer Research (2019)

Targeting nonspecific, tumor-associated antigens (TAA) with chimeric antigen receptors (CAR) requires specific attention to restrict possible detrimental on-target/off-tumor effects. A reduced affinity may direct CAR-engineered T (CAR-T) cells to tumor cells expressing high TAA levels while sparing low expressing normal tissues. However, decreasing the affinity of the CAR-target binding may compromise the overall antitumor effects. Here, we demonstrate the prime importance of the type of intracellular signaling on the function of low-affinity CAR-T cells.We used a series of single-chain variable fragments (scFv) with five different affinities targeting the same epitope of the multiple myeloma-associated CD38 antigen. The scFvs were incorporated in three different CAR costimulation designs and we evaluated the antitumor functionality and off-tumor toxicity of the generated CAR-T cells in vitro and in vivo.We show that the inferior cytotoxicity and cytokine secretion mediated by CD38 CARs of very low-affinity (Kd < 1.9 × 10-6 mol/L) bearing a 4-1BB intracellular domain can be significantly improved when a CD28 costimulatory domain is used. Additional 4-1BB signaling mediated by the coexpression of 4-1BBL provided the CD28-based CD38 CAR-T cells with superior proliferative capacity, preservation of a central memory phenotype, and significantly improved in vivo antitumor function, while preserving their ability to discriminate target antigen density.A combinatorial costimulatory design allows the use of very low-affinity binding domains (Kd < 1 μmol/L) for the construction of safe but also optimally effective CAR-T cells. Thus, very-low-affinity scFvs empowered by selected costimulatory elements can enhance the clinical potential of TAA-targeting CARs.